The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.La présente invention concerne des procédés pour la gestion du poids dun individu le nécessitant par la détermination du niveau de suffisance rénale de lindividu et prescription ou administration à lindividu dune quantité thérapeutiquement efficace de (R)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine ou dun sel, solvate ou hydrate pharmaceutiquement acceptable de celle-ci, à condition que lindividu ait un niveau de suffisance rénale choisie dans le groupe consistant en : insuffisance rénale inexistante, insuffisance rénale légère et insuffisance rénale modérée. De plus, linvention concerne un procédé de sélection dun individu pour un traitement au moyen de (R)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine ou dun sel, solvate ou hydrate pharmac
